The proposed deal between Novo Holdings and contract manufacturer Catalent may face headwinds from an increasingly aggressive U.S. Federal Trade Commission.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,